MDM2 and melanoma: Intriguingly, mutually exclusive focal amplification of MDM2 or inactivating mutation in TP53 have been shown to be enriched in BRAF-, NRAS-, and NF1-wild-type human melanoma, although human TP53-mutant melanomas tend to also display higher mutation burden and presence of C>T transitions [98].